lifestyle.epubzone.org

Author: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026

May 12, 2026
BlossomHill Therapeutics Presents First Preclinical Data from New Pan-KRAS Inhibitor Program Built on a Novel Chemical Scaffold During Mini Symposium at AACR 2026

April 22, 2026
BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026

March 17, 2026